Form 4: Neogenomics COO Sells Shares, Details Equity Holdings
Insider Transaction Report
Neogenomics' President and Chief Operating Officer, Warren Stone, reported the sale of 22,128 shares of common stock and detailed his extensive equity holdings, including various stock options and restricted units.
Summary
- Warren Stone, President & Chief Operating Officer of Neogenomics Inc. (NEO), reported the sale of 22,128 shares of common stock.
- The transaction occurred on January 20, 2026, at a price of $12.5037 per share, totaling approximately $276,679.97.
- The sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
- Following the transaction, Mr. Stone directly beneficially owns 121,631 shares of common stock.
- Mr. Stone holds a significant number of derivative securities, including 530,186 stock options with various exercise prices and expiration dates up to April 1, 2035.
- He also holds 64,442 performance stock units (PSUs) and 210,406 restricted stock units (RSUs) with different vesting schedules, some tied to company performance goals.
- His promotion to President & Chief Operating Officer on April 1, 2025, led to an acceleration of vesting schedules for certain stock options and restricted stock units granted on February 21, 2025.
Sentiment
Score: 5
Explanation: The filing reports an insider sale of common stock, which can be perceived as slightly negative. However, the transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged sale and mitigating concerns about opportunistic trading. The detailed disclosure of equity compensation provides transparency.
Positives
- The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged sale and potentially reducing concerns about opportunistic insider trading.
- Detailed disclosure of executive equity compensation, including stock options, performance stock units, and restricted stock units, provides transparency regarding management's alignment with shareholder interests.
Negatives
- President & COO Warren Stone sold 22,128 shares of common stock, which can sometimes be perceived negatively by the market, even if pre-scheduled.
Risks
- Potential for negative market perception due to an insider selling shares, despite the transaction being pre-scheduled under a Rule 10b5-1 plan.
Future Outlook
NA
Management Comments
- Warren Stone was promoted to President & Chief Operating Officer on April 1, 2025.
- In connection with Mr. Stone's promotion, the vesting schedules for certain stock options and restricted stock units granted on February 21, 2025, were modified to accelerate vesting.
Industry Context
NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | Warren Stone | April 1, 2025 | Promotion |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Policy Adjustment | Vesting schedules for stock options and restricted stock units granted on February 21, 2025, were modified to vest ratably on the 12-month, 18-month, and 24-month anniversary dates of the grant date, accelerated from the original three-year ratable vesting, in connection with Mr. Stone's promotion. | April 1, 2025 | Accelerates the realization of equity compensation for a key executive, potentially enhancing retention and aligning interests with shorter-term performance goals. |
Stakeholder Impact
- Shareholders: May interpret the insider sale differently (neutral to slightly negative), but benefit from transparency in executive compensation and the pre-scheduled nature of the transaction.
- Employees: The promotion and accelerated vesting for a key executive could signal opportunities for career progression and performance-based rewards within the company.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Grant date for 166,113 stock options. |
| 05/11/2023 | Grant date for 53,969 stock options, 21,204 performance stock units, and 28,838 restricted stock units. |
| 02/23/2024 | Grant date for 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Grant date for 29,976 stock options, 17,905 restricted stock units, and 17,908 performance stock units. |
| 02/21/2025 | Grant date for 143,266 stock options and 84,317 restricted stock units. |
| 04/01/2025 | Warren Stone's promotion to President & Chief Operating Officer; also grant date for 94,518 stock options and 52,687 restricted stock units. |
| 01/13/2026 | Vesting date for 59,382 restricted stock units. |
| 01/20/2026 | Date of common stock transaction (sale). |
| 01/21/2026 | Signature date of the reporting person's attorney-in-fact. |
| 05/11/2026 | Expiration date for 21,204 performance stock units. |
| 02/23/2027 | Expiration date for 25,330 performance stock units. |
| 05/02/2027 | Expiration date for 17,908 performance stock units. |
| 12/01/2029 | Expiration date for 166,113 stock options. |
| 05/11/2030 | Expiration date for 53,969 stock options. |
| 02/23/2034 | Expiration date for 42,344 stock options. |
| 05/02/2034 | Expiration date for 29,976 stock options. |
| 02/21/2035 | Expiration date for 143,266 stock options. |
| 04/01/2035 | Expiration date for 94,518 stock options. |
Recommendation
holdThe filing details a pre-scheduled insider sale by a key executive, which is a routine event under a Rule 10b5-1 plan and does not inherently signal a change in company fundamentals or future prospects. While insider selling can sometimes be viewed negatively, the pre-arranged nature mitigates concerns of opportunistic trading. The extensive equity holdings of the executive also indicate continued alignment with shareholder interests. Therefore, a "hold" recommendation is appropriate as this filing does not present new information that would significantly alter the investment thesis.
Keywords
Neogenomics, NEO, Form 4, insider trading, stock options, restricted stock units, performance stock units, executive compensation, Warren Stone, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.